End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
24.15 CNY | -4.55% | +2.85% | +41.15% |
Strengths
- Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
- The group's high margin levels account for strong profits.
- Analysts covering this company mostly recommend stock overweighting or purchase.
Weaknesses
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+41.15% | 1.97B | - | ||
+35.04% | 5.92B | B- | ||
-15.13% | 4.51B | C+ | ||
-9.46% | 3.15B | B- | ||
+0.51% | 3.1B | C | ||
-3.53% | 2.42B | - | D+ | |
-5.15% | 1.68B | - | - | |
+0.09% | 1.65B | - | - | |
-12.97% | 1.53B | C- | ||
+33.40% | 1.38B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 600285 Stock
- Ratings Henan Lingrui Pharmaceutical Co., Ltd.